Drug Approvals After First-Cycle Review Decline, Parexel Report Finds

FDA's Center for Drug Evaluation & Research cleared fewer NDAs after one review in 2005 than it did the previous year, according to Parexel International's Bio/Pharmaceutical R&D Statistical Sourcebook 2007/2008